Jade Biosciences, Inc.
JBIOHeld by 7 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying7 funds opened new positions. Next phase2 readout (JADE101): Jan 2029. Short interest: 23.3% of float.
Held by 7 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying7 funds opened new positions. Next phase2 readout (JADE101): Jan 2029. Short interest: 23.3% of float.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.